Helminth Infections and Cardiovascular Diseases: *Toxocara* Species is Contributing to the Disease

Mohammad Zibaei*

Department of Parasitology and Mycology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

**Abstract:** Toxocariasis is the clinical term used to describe human infection with either the dog ascariid *Toxocara canis* or the feline ascariid *Toxocara cati*. As with other helminths zoonoses, the infective larvae of these *Toxocara* species cannot mature into adults in the human host. Instead, the worms wander through organs and tissues, mainly the liver, lungs, myocardium, kidney and central nervous system, in a vain attempt to find that, which they need to mature into adults. The migration of these immature nematode larvae causes local and systemic inflammation, resulting in the “larva migrans” syndrome. The clinical manifestations of toxocariasis are divided into visceral larva migrans, ocular larva migrans and neurotoxocariasis. Subclinical infection is often referred to as covert toxocariasis. One of the primary causes of death all around the world is cardiovascular disease that accounted for up to 30 percent of all-cause mortality. Cardiovascular disease and more precisely atherosclerotic cardiovascular disease, is predicted to remain the single leading cause of death (23.3 million deaths by 2030). A-quarter of people presenting the disease does not show any of the known cardiovascular risk factors. Therefore, there is considerable interest in looking for novel components affecting cardiovascular health, especially for those that could improve global cardiovascular risk prediction. This review endeavours to summarize the clinical aspects, new diagnostic and therapeutic perspectives of toxocaral disease with cardiovascular manifestations.

**Keywords:** Toxocariasis, cardiovascular, visceral larva migrans, epidemiology.

**INTRODUCTION**

*Toxocara canis* (*T. canis*) and *Toxocara cati* (*T. cati*), roundworms of dogs and cats, are probably the most common gastrointestinal zoonotic helminths of domestic canids and felids world-wide [1]. Natural hosts as well as paratelic hosts, including the human become infected by ingesting either embryonated eggs containing third-stage larvae, from soil (geophagia, pica), dirty hands or raw vegetables, or larvae from undercooked giblets, meat or offals [2]. *Toxocara* larvae hatch in the stomach and migrate into the mucosa of upper small intestine and penetrate via blood and lymphatic vessels throughout the body, resulting in somatic in many types of tissues. The liver is an important site for controlling the migration of *Toxocara* larvae. Dissemination occurs via the blood-borne rout, through tissues and body cavities [3]. The classical clinical syndromes of *Toxocara* infection are divided into visceral larva migrans (VLM) and ocular larva migrans (OLM). VLM syndrome most commonly affects the liver, skin, and lungs, but involvement of the central nervous system and myocardium are rare. In OLM, migrating larvae can induce granulomatous retinal lesion, which are characterized by complaints of loss of visual acuity, squint and seeing lights. A third clinical syndrome, called covert toxocariasis (CT), was found in patients with clinical symptoms that are non-specific by itself and do not fall within the categories VLM or OLM, but form together a vague complex of symptoms [4]. The prevalence of patent *Toxocara* infections is highest in dogs and cats and in much less common in adult animals in many countries all over the world [5]. Several epidemiological and clinical studies have reported that regular contact to dog and cats, rural residence, geophagia or dementia has been identified as risk factors for the acquisition of human *Toxocara* infection [6-10].

One of the primary causes of death all around the world is cardiovascular disease that accounted for up to 30 percent of all-cause mortality [11]. Cardiovascular disease and more precisely atherosclerotic cardiovascular disease, is predicted to remain the single leading cause of death (23.3 million deaths by 2030) [12]. Despite the fact that major risk factors for cardiovascular disease have been firmly established, twenty-five percent of people presenting the disease do not...
show any of the known cardiovascular risk factors [13]. Therefore, there is considerable interest in looking for novel components affecting cardiovascular health, especially for those that could improve global cardiovascular risk prediction.

Based upon the immuno-inflammatory response elicited by infectious disease, the parasitological contribution to atherosclerosis, the pathological basis of the vast majority of cardiovascular disease, represents a long-standing controversy [14, 15].

Previous studies have suggests that some parasitic agents such as Trypanosoma cruzi, cause Chagas disease, might contribute to atherosclerotic vascular diseases [16]. In human toxocariasis (VLM syndrome) the larvae can enter the liver, the lung, the kidney, brain or the heart. The association between Toxocara spp infection and vasculitis manifestations is unusual but has been previously reported [17, 18].

To improve knowledge regarding the role of Toxocara in contributing to the disease, the present review conducted to the clinical manifestation cardiovascular consequences, diagnostic and treatment perspectives in human toxocariasis.

AGENTS

Toxocara species are nematodes, taxonomically included within the order and family Ascaridida.

Our concept is *T. canis* is more important than *T. cati* in causing human infection and disease because cats, not dogs, bury Toxocara ova contamination faeces, making infectious ova less accessible to susceptible individuals. Further reasons include the fact that morphometry of larvae in histological sections and early serology, using cross-reactive antigens include the fact that morphometry of larvae in his- tological sections and early serology, using cross-reactive antigens, failed to implicate *T. cati* over *T. canis* in human cases and also the lesser tendency for brain involvement in the murine model of *T. cati* toxocariasis [19]. Based on generalized exclusion, *T. canis* was deemed to be the more important aetiological agent of human toxocariasis.

There are reports on the location of *T. cati* larvae in paratenic hosts as a causative agent of toxocariasis in human [20]. Both visceral toxocariasis and ocular larva migrans, caused by migrating larvae, as well as adult *T. cati* infections of humans have been described [20]. *T. cati* has been reported in case of decreased visual acuity caused by a macular lesion of the eye, where the patient’s serum was positive reactive to *T. cati* antigens [21]. The studies by Zibaie et al. showed the role of *T. cati* in Toxocara infections of animal model [22, 23].

LIFE CYCLE

A wide variety of animals, including humans can become infected with *Toxocara* species by ingesting eggs contain larvae from contaminated soil and the consumption of contaminated raw meat or liver. In the paratenic or transport hosts, the larvae do not develop to maturity, but migrate for months throughout host tissues before lodging within host tissues in state of arrested development. The larvae do not encyst but remain exposed to the host environment, absorbing nutrients across the nematode cuticle. The larvae can survive in tissue for several years despite vigorous host immunologic responses to parasite antigens (Fig. 1).

EPIDEMIOLOGY

*T. canis* and *T. cati* are nematode, which infects canines and felines worldwide, respectively, and as widespread environmental results dissemination of them ova in hosts faeces, other unnatural or paratenic hosts contains earthworms, ants, poultry, cockroach, and mammals are contacted to the parasite. These nematodes appear to have caused disease for millennia [24]. Toxocariasis in man is presumed to be contracted through the ingestion of eggs from contaminated soil (sapro-zoonosis); children with pica and contact to puppies appear to be particularly vulnerable [25]. Recent date suggests that dogs affected with *T. canis* may cause people infected through direct contact [26]. Additional risk factors include mental retardation requiring institutionalization and ingestion meat from paratenic hosts such as chicken and lamb [27-30]. Cats and other felines act as definitive hosts for the cat roundworm, *T. cati*, which is responsible for toxocariasis. The majority of reported human cases of toxo- cariasis in the past have been associated with *T. canis* not with *T. cati*. The habit of cats covering their faeces in soil tends to prevent the spread of eggs, give further support to this preference for *T. canis* infection [31]. For religious reasons, dogs are avoided in the more of Islamic regions, whereas cats are favorite pet. Worldwide studies of *T. canis* and *T. cati* have demonstrated a distribution between 1-45% and 0.8-59.3% in dogs and cats, respectively [32, 33].

Because toxocariasis does not become patent in humans, estimates of prevalence of humans depend on immunosurveys. These sero-epidemiologic surveys revealed wide difference depending on the man tested. The seroprevalence of most adults were 3.1% in Spain and 7.5% in Australia (developed countries), but the higher seroprevalence of *Toxocara* infection was found in 30.4% in Nigeria and 20.5% in Brazil (developing countries and tropical regions) [34-37]. Serological studies demonstrated primarily among children in developed countries have indicated sero-prevalence levels of *T. canis* in New Zealand (0.7%), Japan (1.6%), Denmark (2.4%), Australia (7.5%), the United States (14%), and 15% in Poland [32, 38, 39]. By contrast, the higher values of seroprevalence have been revealed in tropical and tropical regions or developing countries including Nigeria (30%), Swaziland (45%), La Reunion (93%), Nepal (81%), Indonesia (63.2%), Malaysia (58%), Brazil (36%) and 37% in Peru [40-42].

PATHOGENESIS

The compounds surface coat of *Toxocara* larvae is a dynamic structure that turns over quite rapidly and generates large quantities of glycosylated excretory-secretory proteins [43]. Majority of these proteins are formed a family of highly antigenic mucins that induce the cellular immunity, which determined by the secretion of cytokines that increasing of eosinophilia and the production of IgE antibodies [44]. The recruited eosinophils adhere to a membranous layer that is frequently detached from larval epicuticle, allowing the antigens [45]. *Toxocara* larva elicits humoral and cellular immune responses in humans. Due to host inflam-
Inflammatory responses tissues damage is more than the infection itself. In *Toxocara* infection, larval antigens induce granulomatous inflammation with eosinophils, histocysts and fibrous tissue. The granulomatous are found most often in liver and less in the lungs, eyes, brain, and the other organs. These eosinophil-mediated granulomatous responses are almost exclusively responsible for the clinical manifestation of *Toxocara* infection including overt toxocariasis (VLM and OLM), and covert toxocariasis (Table 1).

**CHRONIC HELMINTHIC INFECTION AND ATHEROSCLEROSIS**

The causative agents and processes, which may be involved in the pathogenesis of atherosclerosis, are being interested. The occurrence rate of atherosclerosis and cardiovascular diseases are much lower in developing countries. Due to the present knowledge of immune and infectious mechanisms related to atherosclerosis, it is proposed that chronic helminthic infections can have a significant bearing on the epidemiology of cardiovascular diseases.

Helminth infection can be increased the risk of atherosclerosis: (1) helminths evade or suppress host immune responses, by producing anti-inflammatory and other immunomodulatory molecules; (2) helminths induce chronic Th2 activation, which can modify cytokine profiles and immunological responses to heat shock proteins (HSP); (3) The chronic Th2 profile may modulate monocyte and macrophage activation and chemotaxis to inflammatory sites (atherosclerotic plaques); (4) Chronic Th2 activation may lead to a cytokine profile that could be beneficial for attenuation of atherosclerosis development (involved in producing IL-4, IL-10 and IL-13 and inhibition of proinflammatory cytokines); and (5) helminthic infections may reduce plasma LDL level not only by affecting the host nutrition, but also via modulation of naturally occurring antibodies to cholesterol [46].

Since the *Toxocara* species can be cause chronic parasitic infection and considering that a link between atherosclerosis and helminth infections has not been investigated, studies are needed to clarify these suggestions.

**TOXOCARA INFECTION AND CARDIOVASCULAR DISEASE**

Human toxocariasis is widespread as evidenced by seropositivity. Ocular toxocariasis is almost certainly an organ specific subdivision of visceral toxocariasis. Visceral toxocariasis may be overt or covert. Covert toxocariasis is much more common than overt toxocariasis. Initial reports of overt toxocariasis were of severe cases in children under the age of four years [47]. Extreme eosinophilia (50% or more of the total white blood cell count) was regarded as an essential criterion for diagnosis with varying accompanying features of increasing the body temperature (fever), pulmonary infiltration, hepatosplenomegaly, muscle and joint pains, abdominal pain, and cardiac involvement rarely occurs but can be serious [48, 49].

**Eosinophilic Myocarditis**

Myocardial damage and endomyocardial fibrosis has been associated clinically with chronic eosinophilia [50].
Chronic eosinophilia can be due to helminthic infection such as toxocariasis, drug reactions, allergic disorders, or other causes. Dramatic eosinophil counts (up to 90 percent), may occur in patients as VLM, who often present with leukocytosis. Visceral larva migrans syndrome results from the ingestion of embryonated eggs of *Toxocara* spp. After ingestion, hatching occurs in duodenum (upper small intestine). The larvae penetrate into the mucosa and via the portal circulation migrate to the liver, heart, lungs and enter systemic circulation. Because the larvae size is larger than diameter blood vessels, it may bore through the vessel wall of the host, migrate within the tissues, and elicit an immune response. Eventually, a larva becomes enmeshed in a fibrotic encapsulated granuloma [51-53]. Severe myocarditis ensues when the third-stage larvae (L3) invade cardiac tissue (Fig. 2). Several cases of myocarditis associated with VLM syndrome have been reported [54]. Myocarditis may occur in up to 15 percent in patients with visceral larva migrans and the myocarditis is accompanied by significantly increased levels of circulating eosinophils in all of patients. Brockington and Olsen [55] described that eosinophilic endomyocardial disease occurs in three stages: I) the acute necrotic stage, the thrombotic stage, and the late fibrotic or end stage. The acute necrotic stage is seen in patients ill for only a few weeks, and is characterized by areas of acute necrosis and inflammatory cell infiltrates into the endomyocardium, with focal areas of damage to the subendocardium, II) the second stage, after several months, begins when a layer of granulation tissue develops between the endocardium and subendocardium, accompanied by intraventricular thrombi and thrombi in small and medium sized blood vessels, and III) the end stage occurs when dense endomyocardial fibrosis is seen that produces a restrictive myocardioaphy. Friedman and Hervada in 1960 described a child with strong evidence of toxocarial infection who suffered from severe myocarditis that resolved on treatment [56]. Spry *et al.* described myocardial lesions in patients with eosinophilic endomyocarditis and tropical endocardia fibrosis [57]. In a case of *Toxocara* infection associated with myocarditis has previously been shown in which elevated C-reactive protein (1.4 mg/dl), creatinine phosphokinase (679 IU/l), aspartate aminotransferase (124 IU/l), alanine aminotransferase (182 IU/l) and lactic dehydrogenase (733 IU/l) [58].

**Pericarditis and Pleural Effusion**

The clinical spectrum of *Toxocara* infection is broad, producing pulmonary effusion, cardiac tamponade, and ascites [59-61]. Less commonly, toxocariasis can be self-limiting with few clinical manifestations. A case report revealed systemic effusion in a woman cardiomycitis with congestive heart failure, serositis with collagen vascular disorders. Elevation in with blood cell count (13,900/μl) with 5% eosinophils, serum brain natriuretic peptide to 340 pg/ml (normal < 18.4 pg/ml), and chest roentgenogram with chest computed tomography has been observed in patient diagnosed with toxocariasis- associated pericarditis [62]. Bachmeyer *et al.* in a case found fever, night sweats, weight loss, hilar and mediastinal lymphadenopathy, bilateral pleural effusion, and eosinophilia- mimicking lymphoma related to *T. canis* infection [59]. The patient appeared pneumonia with eosinophilia that responsible for acute respiratory disorders. The patient was healthy (physical examination) and her medical history was unremarkable. Laboratory examinations of the peripheral blood showed the white blood cells count 10.8 × 10^9/μl with eosinophilia (26%). Results of serum electrophoresis revealed an albumin level of 32.8 g/l (normal range more than 39 g/l); α2-globulin, 9.8 g/l (normal range more than 7 g/l); and polyclonal γ-globulinemia, 16.9 g/l (normal range more than 10 g/l). After diagnosis the disease, the patient treated with oral albendazole (400 mg daily for 10 days). Unusually, in a case of life-threatening *Toxocara* infection, Henry *et al.* demonstrated that the chest roentgenograms was revealed bilateral pleural effusion with normal parenchyma but an enlarged cardiac image [63]. Laboratory tests showed a leukocyte count of 15.4 × 10^9/mm³ with 2.2 × 10^9 eosinophils/mm³. On pericardiotomy of the patient, more than 800 ml of pericardial fluid with a cellular component of 20% eosinophils evacuated. Serology was positive for *T. canis* antibodies. On basis of the clinical pictures and the conducted tests a diagnosis of acute toxocariasis was established; ivermectin 200 μg/kg/day at day 10 and day 25 was applied in treatment.

**LABORATORY DIAGNOSIS**

The diagnosis of toxocariasis, like most parasitic infection, is made initially on clinical signs such as hepatomegaly, fever or wheezing, with confirmatory testing playing a sec-

---

Table 1. Clinical forms of *Toxocara* infection and logical reasons for clinical treatment and prevention.

| Clinical forms       | Signs and Symptoms | Eosinophilia | Serology | Clinical | Prevention/Control |
|----------------------|--------------------|--------------|----------|----------|--------------------|
| Visceral Larva Migrans | High/Mild          | High         | High/Mild | Yes°     | Yes°**             |
| Ocular Larva Migrans  | High               | Doubtful     | Mild     | Yes      | Yes               |
| Neurotoxocariasis     | Mild               | Doubtful     | Mild     | Yes      | Yes               |
| Covert toxocariasis   | Doubtful           | Doubtful     | Mild     | Yes      | Doubtful           |
| Asymptomatic toxocariasis | None            | Doubtful     | Mild     | No       | Doubtful           |

° In cases of clinical toxocariasis, thiabendazole (15 mg/kg/body weight/day) for 5 days.

** Positive results for eosinophilia and serological tests.
secondary role. Blood cells count always showed the presence of blood eosinophilia, which was usually marked and was sometimes massive: approximately $1 \times 10^3$ cells/mm$^3$ [64-66]. In the absence of hepatomegaly, the symptoms and signs of toxocariasis mimic tropical pulmonary eosinophilia.

Diagnosis of human toxocariasis is confirmed by visual methods (as called the gold standard). Microscopic observation of biopsies or organ fragments can find larval sections or debris [67, 68]. Other laboratory results include increase in immunoglobulin and elevated isomemagglutinin titers to A and B antigens (blood group antigens) [69]. Radiographic imaging of involved organs using ultrasound, computed tomography (CT) scan, and magnetic resonance imaging (MRI) can describe focal lesions [70]. Advance in serological techniques was obtained due to the difficulties and uncertainties of direct visual detection. The diagnosis is most established by confirmatory serological testing using an ELISA (enzyme linked-immunosorbent assay) that detecting IgG antibodies against TES (Toxocara excretory-secretory) antigens (TES-ELISA). ES proteins from second stage $T. \ canis$ or $T. \ cati$ larvae maintained in vitro form the substrate for ELISA [71, 72]. The sensitivity and specificity have been estimated to be approximately 78.0% and 92.0% for $T. \ canis$ and 97.0% and 96.7% for $T. \ cati$, respectively [73-75]. Limited data indicate no significant cross-reactivity in individuals infected with common helminthic infections [76, 77]. A Western blotting assay using TES antigens is more specific [75, 78]. In the past decade, immunoblot assays have been developed using recombinant ES proteins [79, 80]. Antigens capture tests using monoclonal antibody to toxocaral ES proteins offers the ability to distinguish current infection [81].

Molecular diagnostic methods have proven to be useful to investigate parasite in tissue fragments from surgical operations or dissections and in cerebrospinal fluid, but this approach are currently not used practically [23, 82-84].

**TREATMENT AND PROGNOSIS**

The majority of patients with *Toxocara* infection do not require treatment, since toxocarial infections are usually subclinical and self-limited, nevertheless, the disease can be fatal with severe clinical manifestation. Treatment is generally reserved for cases with severe toxocariasis, although this remains a controversial point. Usually, acute toxocariasis is treated either symptomatic or with specific anti-parasitic treatment, depending on the severity of clinical disease. Patients with either peripheral eosinophilia or mild toxocariasis are often treated cautiously. Asymptomatic cases with increased eosinophils and those with mild *Toxocara* infection in the absence of increased eosinophils normally do not need any special treatment. Mebendazole, albendazole, thiabendazole, ivermectin and diethylcarbamazine have been reported as treatment for human toxocariasis. In cases of clinical toxocariasis, thiabendazole (15 mg/kg/day) appeared to be effective; however, a similar course of albendazole resulted in more frequent clinical cure and a measurable decrease in eosinophils count. A dose of 400 mg of albendazole twice a day for 5 days is the currently recommended therapy [84]. A twenty-one days course of mebendazole with dose of 20-25 mg/kg/day has been shown to be effective, alternatively [85]. Severe symptomatic treatments, including either albendazole or mebendazole, and corticosteroids (prednisone) with dose of 0.5-1.0 mg/kg daily are often administered concomitantly.

Abe et al., in a case report demonstrated that a 4-weeks course of oral albendazole and prednisolone results in resolution of clinical symptoms in myocarditis-associated with *Toxocara* infection [58]. Enko and colleagues reported a case of fulminant eosinophilic myocarditis associated with toxocariasis that treated with both oral albendazole for four weeks and intravenous methylprednisolone (~500 mg/d) for 3 days, followed by oral medications of prednisolone (50 mg/d) for 2 weeks. Following treatment with those drugs, significantly improved ventricular function and quickly reduced the number of eosinophils and normalized [86].

**CONCLUDING REMARKS**

*Toxocara canis* and *Toxocara cati*, roundworms of dogs and cats respectively, are zoonotic parasites that cause widespread and common human toxocariasis. The infective larvae both *Toxocara* species cannot mature into adults in the human host. The worms wander through tissues and organs in a vain attempt to find that which they need to mature into adults. A variety of disease states are described but symp-
Toxocara Infection and Cardiovascular Diseases

REFERENCES

ACKNOWLEDGEMENTS

Declared none.

toms are not well understood and require further elucidation. The migration of immature larvae causes local and systemic inflammation, resulting in the “larval migrans syndrome”. Visceral larva migrans is defined not only by chronic increased eosinophils and increased γ-globulin in the blood, but also by involvement of the liver, lungs, eyes, the cerebral nervous system, skin and the heart as a result of migration the local larval. In toxocariasis inflammation of the heart muscle (myocarditis) may be caused by direct larval invasion to the myocardium and hypersensitivity reactions to the parasite. Several cases of pleural effusion and pericardial associated with Toxocara infection have been reported. With the exception of overwhelming infections, widespread of small numbers of tissue-dwelling larvae dictates that serology tool of choice for diagnosing human infection. Strategies for the treatment of this disease in human, is use of mebendazole, albendazole, thiabendazole, ivermectin, diethylcarbamazine with corticosteroids.

CONFICT OF INTEREST

The author confirms that this article content has no conflict of interest.

REFERENCES

[1] Despommier D. Toxocariasis: clinical aspects, epidemiological, medical ecology and molecular aspects. Clin Microbiol Rev 2005; 16: 265-72.
[2] Schantz PM. Toxocara larva migrans now. Am J Trop Med Hyg 1998; 41: 21-34.
[3] Rubinsky-Elefant G, Hirata CE, Yamamoto JH, Ferreira MU. Human toxocariasis: diagnosis, worldwide seroprevalences and clinical expression of the systemic and ocular forms. Ann Trop Med Parasitol 2010; 104: 3-23.
[4] Glickman LT, Lafferty KJ. Epidemiology and pathogenesis of zoonotic toxocariasis. Epidemiol Rev 1981; 3: 230-50.
[5] Castillo D, Parades C, Zanartu C. Environmental contamination with Toxocara spp. eggs in public squares and parks from Santiago, Chile. Bol Chil Parasitol 2000; 55: 66-91.
[6] Dubinsky P, Hasevivas-Reitertova K, Petko. Role of small mammals in the epidemiology of toxocariasis. Parasitology 1995; 110: 187-93.
[7] Giacometti A, Cirioni O, Fortuna M. Environmental and serological evidence for the presence of toxocariasis in the urban area of Ancona, Italy. Eur J Epidemiol 2000; 16: 1023-6.
[8] Zibaei M, Sadjadi SM, Saraki B. Prevalence of Toxocara catti and other intestinal helminths in stray cats in Shiraz, Iran. Trop Biomed 2007; 24: 39-43.
[9] Mizgajska, H. Eggs of Toxocara spp. in the environment and their public health implications. J Helminthol 2001; 75: 147-51.
[10] Uga S. Prevalence of Toxocara eggs and number of fecal deposits from dogs and cats in sandpits of public parks in Japan. J Helminthol 1993; 67: 78-82.
[11] World Health Organization. Global status report on communicable diseases 2010. Geneva: World Health Organization, 2011.
[12] Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.
[13] Magnus P, Beagelho R. The real contribution of the major risk factors to the coronary epidemics: time to end the only 50% myth. Arch Intern Med 2001; 161: 2657-60.
[14] Nieto FJ. Infective agents and cardiovascular disease. Semin Vasc Med 2002; 2: 401-15.
[15] Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106: 858-67.
[16] Frustaci M, Francone N, Petrosovlo, Chimienti C. High prevalence of myocarditis in patients with hypertensive heart disease and cardiac deterioration. Eur J Heart Fail 2013; 15: 284-91.
[17] Hamidou MA, Gueglio B, Cassagneau E, Treweck D, Groolleau JY. Henoch-Schönlein purpura associated with Toxocara canis infection. J Rheumatol 1999; 26: 443-5.
[18] Pawlowska-Kamieniak A, Mroczkowska-Juchkiewicz A, Papierzowski A, Henoch-Schönlein purpura and toxocariasis. Pol Merkur Lek 1998; 4: 217-8.
[19] Hasaviova-Reitertova K, Tomasovicova O, Dubinsky O. Effect of various doses of injective Toxocara canis and Toxocara catti eggs on the humoral response and distribution of larvae in mice. Parasitol Res 1995; 81: 13-7.
[20] Fisher M. Toxocara catti: zoonosis or not zoonosis. Trends Parasitol 2003; 19: 167-70.
[21] Zibaei M, Sadjadi SM, Jahadi-Hosseini SH. Toxocara catti larvae in the eye of a child: a case report. Asian Pac J Trop Biomed 2014; 4 (Suppl 1): S53-5.
[22] Zibaei M, Sadjadi SM, Uga S. Experimental Toxocara catti infection in gerbils and rats. Korean J Parasitol 48; 4: 331-3.
[23] Zibaei M, Sadjadi SM, Karamian M, Uga S, Orayn A, Jahadi-Hosseini SH. A comparative histopathology, serology and molecular study, on experimental ocular toxocariasis by Toxocara catti in Mongolian gerbils and Wistar rats. BioMed Res Int 2013; 2013: 109580.
[24] Bouchet F, Araujo A, Harker S, et al. Toxocara canis (Werner, 1782) eggs in the Pleistocene site of Menez-Dregan, France (300,000-500,000 years before present). Mem Inst Oswaldo Cruz 2003; 98(Suppl): 137-9.
[25] Marmor M, Glickman L, Shofer F, et al. Toxocara canis infection of children: Epidemiologic and neuropsychologic findings. Am J Public Health 1987; 77: 554-9.
[26] Wolfe A, Wright IP. Human toxocariasis and direct contact with dogs. Vet Rec 2003; 152: 419-22.
[27] Huminer D, Symon K, Groskopf L, et al. Seroepidemiologic study of toxocariasis and Strongyloidiasis in institutionalized mentally retarded adults. Am J Tropical Med Hyg 1992; 46: 278-81.
[28] Sturchler D, Weiss N, Gassner M. Transmission of toxocariasis. J Infect Dis 1990; 162: 571.
[29] Salem G, Schantz P. Toxocara visceral larva migrans after ingestion of lamb liver. Clin infect Dis 1992; 15: 743-4.
[30] Nagakura K, Tachibana H, Kaneda Y, Kato Y. Toxocariasis possibly caused by ingesting raw chicken. J Infect Dis 1989; 160: 735-7.
[31] Zibaei M, Uga S. Contamination by Toxocara spp. Eggs in sandpits in Kobe, Japan. J Environ Cont Tech 2008; 26: 32-7.
[32] Fan CK, Liao CW, Cheng YC. Factors affecting disease manifestation of toxocariasis in humans: genetics and environment. Vet Parasitol 2013; 193: 342-52.
[33] Mikaelli F, Mirhendi H, Hosseini M, Asgari Q, Kia EB. Toxocara nematodes in stray cats from Shiraz, southern Iran: intensity of infection and molecular identification of the isolates. Iran J Parasitol 2013; 8: 593-600.
[34] Nicholas WL, Stewart AC, Walker JC. Toxocariasis: a serological survey of blood donors in the Australian Capital Territory together with observations on the risks of infection. Trans R Soc Trop Med Hyg 1986; 80: 217-21.
[35] Jimenez J, Valladares B, Fernandez-Palacios JM, de Armas D, del Castillo A. A serologic study of human toxocariasis in the Canary Islands (Spain): environmental influences. Am J Trop Med Hyg 1997; 56: 113-5.
[36] Ananuma FF, Chieffi PP, Correa CR, et al. Human toxocariasis: a zoonoepidemiological survey in the municipality of Campinas (SP), Brazil. Rev Inst Med Trop Sao Paulo 2002; 44: 303-7.
[37] Ajayi OI, Dahunsi DM, Ajayi OO, Alalade AA, Ajayi OO. Frequency of human toxocariasis in Jos, Plateau State, Nigeria. Mem Inst Oswaldo Cruz 2000; 95: 147-9.
[38] Macpherson CN. The epidemiology and public health importance of toxocariasis: a zoonosis of global importance. Int J Parasitol 2013; 43: 999-1008.
[39] Jarosz W, Mrozewska-Wiktor H, Wawrzyniak G. Developmental age, physical fitness and Toxocara infection among lower- secondary students living in rural areas contaminated with Toxocara eggs. Parasitology 2010; 137: 53-63.
[40] Liao CW, Sukati H, D'Alimin P, et al. Seroprevalence of Toxocara canis infection among children in the Kingdom of Swaziland, Southern Africa. Ann Trop Med Parasitol 2010; 104: 73-80.

[41] Roldan WH, Espinoza YA, Huapaya PE, Huiza AF, Sevilla CR, Jimenez S. Frequency of human toxocariasis in a rural population from Cajamarca, Peru determined by DOT-ELISA test. Rev Inst Med Trop Sao Paulo 2009; 51: 67-71.

[42] Schoenardi ER, Scaini CJ, Brods CS, et al. Seroprevalence of Toxocara infection in children from southern Brazil. J Parasitol 2013; 99: 537-9.

[43] Page AF, Rudin W, Fluri E, Blaxter ML, Maizels RM. Toxocara canis: A labile antigenic coat overlaying the epicuticular of infective larvae. Exp Parasitol 2000; 75: 72-86.

[44] Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cell with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 346-50.

[45] Bradley JE, Grieve RB, Rockey JH, Glickman LT. Immune-mediated adherence of eosinophils to Toxocara canis infective larvae: The role of excretory-secretory antigens. Parasite Immunol 1987; 9: 133-43.

[46] Magen E, Borkow G, Bentwich Z, Mishal J, Scharf S. Can worms defend our hearts? Chronic helminthic infections may attenuate the development of cardiovascular diseases. Med Hypotheses 2005; 64: 904-9.

[47] Zibaei M, Sadjjadi SM, Geramizadeh B, Firoozeh F. Hepatic toxocariasis in a child: A case report from Shiraz, Southern Iran. Hepat Mon 2008; 8: 310-2.

[48] Boschetti A, Kasznica J. Visceral larva migrans induced eosinophilic cardiomegaly. A case of sudden death in a child. J Forensic Sci 1995; 40: 1097-9.

[49] De Cock C, Lemaître J, Deuvaret EF. Löffler endomyocarditis: a clinical presentation as right ventricular tumor. J Heart Valve Dis 1998; 7: 668-71.

[50] Spry CJF. Eosinophils and endomyocardial fibrosis: A review of clinical and experimental studies, 1980-86. Pathogenesis of Myocardiitis and Cardiomyopathy. Recent Experimental and Clinical Studies. Edited by Kawai C, Abelmann WH. Tokyo: University of Tokyo Press, 1987.

[51] Glickman LT, Schantz PM. Epidemiology and pathogenesis of zoonotic toxocariasis. Epidemiol Rev 1981; 3: 230-50.

[52] Schantz PM, Glickman LT. Roundworms in dogs and cats: Veterinary and public health considerations. Cont Educ Pract Vet 1981; 3: 773-84.

[53] Schantz PM, Glickman LT. Toxocarial visceral larva migrans. N Engl J Med 1978; 298: 436-9.

[54] Vargo TA, Singer DB, Gillette PC, Fernbach DJ. Myocarditis due to visceral larval migrans. J Pediatr 1977; 90: 322-3.

[55] Brockington IF, Olsen EG. Löffler's endocarditis and Davies' endomyocardial fibrosis. Am Heart J 1973; 85: 308-22.

[56] Friedman S, Hervada AR. Severe myocarditis with recovery in a patient with second-stage larvae of Toxocara canis. J Parasitol 1987; 73: 1334-44.

[57] Kirchner T, Altmann HW. Parasitic larva as a cause of circumscibed liver lesions. Morphology and differential diagnosis. Pathologie 1987; 31: 1-6.

[58] Marty AM. Toxocariasis. In: Meyers WM, Neafie RC, Marty AM, eds. Pathology of Infectious Disease. Washington DC: Lippincott Williams & Wilkins, 1997: 334-9.

[59] Henneman P, Henneman C, Delhey J, Storms R. Toxocariasis: clinical and laboratory features in 54 patients. Am Pediatr Pathol 2003; 8: 31-6.

[60] Enko K, Tada T, Ohgo KO, et al. Fulminant eosinophilic myocarditis associated with visceral larva migrans caused by Toxocara canis infection. Curr Med Res Opin 2009; 7: 1344-5.

[61] Page AP, Rudin W, Fluri E, Blaxter ML, Maizels RM. Toxocara canis: A labile antigenic coat overlaying the epicuticular of infective larvae. Exp Parasitol 2000; 75: 72-86.

[62] Matsuki Y, Fujii T, Nakamura-Uchiyama F, et al. Toxocariasis associated with multiple effusions in the pericardial space, thoracic cavity, and Morrison’s Pouch. Int Med 2007; 46: 913-4.

[63] Henneman P, Henneman C, Delhey J, Storms R. Toxocariasis: clinical and laboratory features in 54 patients. Am Pediatr Pathol 2003; 8: 31-6.

[64] Caldera F, Burlone ME, Genchi C, Pirisi M, Bartoli E. Toxocara cati in children: Clinical and laboratory features in 54 patients. Pediatr Infect Dis 2003; 22: 374-8.

[65] Zibaei M, Sadjjadi SM, Sarkari B, Oryan A, Uga S. In vitro cultivation of Toxocara cati adult worms for production of eggs and evaluation of oviposition. Helminthologia 2009; 1: 28-30.

[66] Glickman L, Schantz P, Dombroske R, Cypess R. Evaluation of serodiagnostic tests for visceral larval migrans. Am J Trop Med Hyg 1978; 27: 492-8.

[67] Zibaei M, Sadjjadi SM, Sarkari B, Uga S. Evaluation of Toxocara cati excretory-secretory larval antigens in serodiagnosis of human toxocariasis. J Clin Lab Anal 2016; 30(3): 248-53.

[68] Thompson DE, Bundy DA, Cooper ES, Schantz PM. Epidemiological characteristics of Toxocara canis zoonotic infection of children in a Caribbean community. Bull World Health Organ 1986; 64: 283-90.

[69] Lynch NR, Hagel I, Vargas V, et al. Comparable seropositivity for ascarisiasis and toxocariasis in tropical slum children. Parasitol Res 1993; 79: 547-50.

[70] Magnaval JF. Comparative efficacy of diethylcarbamazine and albendazole vs. albendazole in treatment of toxocariasis: A clinical trial. Ann Trop Med Parasitol 2009; 83: 473-8.

[71] Zibaei M, Sadjjadi SM, Ishiyama S, Sarkari B, Uga S. Production of monoclonal antibody against Toxocara cati second-stage larvae and its application for the detection of circulation antigens. Hybridoma (Larchmt) 2010; 29: 217-20.

[72] Ishiwata K, Shinozaka Y, Kita K, Nishida H. Identification of tissue embedded ascarid larvae by ribosomal DNA sequencing. Parasitol Res 2004; 95: 50-2.

[73] Caldera F, Burlone ME, Genchi C, Pirisi M, Bartoli E. Toxocara cati: Comparative efficacy of diethylcarbamazine and mebendazole for the treatment of human toxocariasis. Parasitology 1995; 110: 529-33.

[74] Henney P, Henneman C, Delhey J, Storms R. Toxocariasis: clinical and laboratory features in 54 patients. Am Pediatr Pathol 2003; 8: 31-6.

[75] Ehrhardt T, Kornbaum S, Toxocara canis and human toxocariasis. Bulletin de l'Institut Pasteur 1979; 77: 225-87.

[76] Lassmann B, Tsigrelis C, Virk A. 33-years-old woman with marked eosinophilia. Mayo Clin Proc 2007; 82: 103-6.

[77] Mayeux WM, Neafie RC, Marty AM. Toxocariasis: Serological diagnosis by enzyme immunosassay. J Clin Pathol 1979; 32: 284-8.

[78] Kirchner T, Altmann HW. Parasitic larva as a cause of circumscibed liver lesions. Morphology and differential diagnosis. Pathologie 1987; 31: 1-6.

[79] Marty AM. Toxocariasis. In: Meyers WM, Neafie RC, Marty AM, eds. Pathology of Infectious Disease. Washington DC: Lippincott Williams & Wilkins, 1997: 334-9.